Intra Cellular Therapies traded at $131.87 this Tuesday April 1st, decreasing $0.05 or 0.04 percent since the previous trading session. Looking back, over the last four weeks, Intra Cellular Therapies lost 0.45 percent. Over the last 12 months, its price rose by 97.80 percent. Looking ahead, we forecast Intra Cellular Therapies to be priced at 128.97 by the end of this quarter and at 120.64 in one year, according to Trading Economics global macro models projections and analysts expectations.
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company that is focused on the discovery, clinical development, and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company offers CAPLYTA for the treatment of schizophrenia as is typical for antipsychotics. Its lumateperone bipolar depression clinical program consists of three monotherapy studies and one adjunctive study. The Company also initiated its third monotherapy Phase III study, Study 403, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.